134 completed, 57 terminated, 30 unknown, 23 recruiting. 168 Phase 2, 54 Phase 1, 32 Phase 4, 28 Phase 3, 21 Not applicable.
Follow thymoglobulin: new trials by email Literature Review of thymoglobulin trials Research Report on thymoglobulin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Conditioning Regimen Containing Low-Dose ATG for the Treatment of AA Receiving sUCBT Anti-Thymocyte Globulin (Rabbit) (Thymoglobulin®) - Aplastic Anaemia | Phase 2 | Not yet recruiting | Anhui Provincial Hospital | 59 | 2027-08-01 | 2026-10-21 |
| A Study Comparing Siplizumab With Rabbit Anti-Thymocyte Globulin to Help the Body Accept a Kidney Transplant Siplizumab, Rabbit anti-thymocyte globulin - Renal Transplant Failure and Rejection | Phase 2 | Recruiting | Nefro Avillion Clinical Development, LLC | 120 | 2026-06-29 | 2026-10-06 |
| A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New Onset Type 1 Diabetes Anti-thymocyte globulin (ATG), verapamil extended-release capsule, Adalimumab - Type 1 Diabetes, New Onset | Phase 1 / Phase 2 | Recruiting | City of Hope Medical Center | 120 | 2026-03-10 | 2026-10-16 |
| Precision Administration of Anti-thymocyte Globulin With or Without Verapamil Anti-thymocyte globulin (ATG), verapamil extended release capsule, Placebo - Type 1 Diabetes | Phase 2 | Recruiting | University of Florida | 60 | 2025-11-12 | 2025-11-26 |
| TCRαβ-depleted Progenitor Cell Graft With Early Memory T-cell DLI, Plus Selected Use of Blinatumomab, in naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Thymoglobulin, Cyclophosphamide, Fludarabine - Hematologic Malignancy | Phase 1 | Recruiting | St. Jude Children's Research Hospital | 30 | 2025-09-25 | 2026-06-02 |
| Allo HSCT for High Risk Hemoglobinopathies Alemtuzumab, Total Body Irradiation, Cell Infusion - Graft Failure, Sickle Cell Disease | Phase 2 | Recruiting | Masonic Cancer Center, University of Minnesota | 62 | 2024-11-19 | 2026-06-04 |
| 1 vs 7 RATG Infusions in Renal Transplantation RATG, Basiliximab - Kidney Replacement | Active not recruiting | Mario Negri Institute for Pharmacological Research | 75 | 2024-07-30 | 2025-09-04 | |
| MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure. Rituximab, Rabbit ATG, Cyclophosphamide - Severe Aplastic Anemia, Acquired Amegakaryocytic Thrombocytopenia | Phase 2 | Recruiting | Masonic Cancer Center, University of Minnesota | 60 | 2024-06-05 | 2026-06-03 |
| Diabetes Islet Preservation Immune Treatment Anti-Thymocyte Globulin (ATG), Interleukin 2, Exenatide - Diabetes Mellitus, Type 1, Hypoglycemia | Phase 1 / Phase 2 | Withdrawn | Camillo Ricordi and Jay Skyler | 2024-06-01 | 2026-01-15 | |
| Phase III Study Comparing GVHD Prophylaxis With ATG-thymoglobulin to ATLG-grafalon in Elderly Patients With Acute Myeloid Leukemia or Myelodysplasic Syndrome and Receiving an Allogeneic Hematopoietic Stem Cell Transplantation With a 10/10 HLA Matched Unrelated Donor Grafalon, Thymoglobulin - GVHD | Phase 3 | Recruiting | Assistance Publique - Hôpitaux de Paris | 324 | 2023-11-28 | 2026-04-27 |
| STOP-T1D Low-Dose (ATG) Antithymocyte Globulin, Placebo (for ATG) - Diabetes Mellitus, Type 1 | Phase 2 | Terminated | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 2 | 2023-11-01 | 2026-05-07 |
| MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies Fludarabine, Busulfan, Melphalan - Hematologic Malignancy, Acute Leukemia | Phase 2 | Recruiting | Masonic Cancer Center, University of Minnesota | 70 | 2023-05-11 | 2026-04-06 |
| Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome Biospecimen Collection, Bone Marrow Aspiration, Busulfan - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia | Phase 3 | Active not recruiting | Children's Oncology Group | 66 | 2023-03-15 | 2026-07-30 |
| Pediatric Study of GVHD Ppx w/o Calcineurin Inhibitors After Day60 Post First Allo HSCT for Hematological Malignancies. Ruxolitinib, Mesna, Anti-thymocyte globulin (ATG) - Hematologic Malignancy, Myeloid Malignancy | Phase 2 | Terminated | St. Jude Children's Research Hospital | 3 | 2023-03-14 | 2025-10-02 |
| A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT) Fludarabine, Cyclophosphamide, Tacrolimus - Sickle Cell Disease, Thalassemia, Beta | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 24 | 2023-02-09 | 2026-06-03 |
| A Trial Comparing Unrelated Donor BMT With IST for Pediatric and Young Adult Patients With Severe Aplastic Anemia (TransIT, BMT CTN 2202) cyclosporine, Matched Unrelated Donor Hematopoetic Stem Cell Transplant, horse anti-thymocyte globulin (ATG) - Severe Aplastic Anemia | Phase 3 | Terminated | Boston Children's Hospital | 53 | 2023-01-25 | 2026-10-19 |
| Treosulfan-Based Conditioning Regimen Before a Blood or Bone Marrow Transplant for the Treatment of Bone Marrow Failure Diseases (BMT CTN 1904) Treosulfan, Fludarabine Phosphate, Tacrolimus - Bone Marrow Failure Syndrome, Congenital Amegakaryocytic Thrombocytopenia | Phase 2 | Completed | Fred Hutchinson Cancer Center | 40 | 2022-04-19 | 2026-03-09 |
| Pharmacologic Pretransplant Immunosuppression (PTIS) + Reduced Toxicity Conditioning (RTC) Allogeneic Stem Cell Transplantation in Inherited Hematologic Disorders Fludarabine, Dexamethasone, Cyclophosphamide - Stem Cell Transplantation | Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2022-03-02 | 2023-09-21 | |
| Selective CD28 Blockade in Renal Transplant Recipients Lulizumab, Tacrolimus, Thymoglobulin® - Kidney Transplantation, Renal Transplant Recipients | Phase 2 | Withdrawn | National Institute of Allergy and Infectious Diseases (NIAID) | 2022-01-10 | 2023-03-22 | |
| Haplocompatible Transplant Using TCRα/β Depletion Followed by CD45RA-Depleted Donor Lymphocyte Infusions for Severe Combined Immunodeficiency (SCID) Anti-thymocyte globulin (rabbit), Busulfan, Fludarabine - Severe Combined Immunodeficiency | Phase 1 / Phase 2 | Active not recruiting | St. Jude Children's Research Hospital | 4 | 2021-09-02 | 2026-09-16 |
Showing 20 of 276. Sign in to see all of them.
Myelodysplastic Syndromes (44) · Leukemia, Myeloid, Acute (43) · Leukemia (32) · Anemia, Aplastic (31) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (31) · Lymphoma, Non-Hodgkin (26) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (25) · Leukemia, Lymphocytic, Chronic, B-Cell (23) · Hematologic Neoplasms (22) · Hodgkin Disease (22) · Lymphoma (22) · Graft vs Host Disease (19) · Multiple Myeloma (18) · Anemia, Sickle Cell (13) · Myeloproliferative Disorders (13)
M.D. Anderson Cancer Center (36) · National Institute of Allergy and Infectious Diseases (NIAID) (13) · Masonic Cancer Center, University of Minnesota (9) · Northwestern University (9) · Fred Hutchinson Cancer Center (8) · St. Jude Children's Research Hospital (8) · Genzyme, a Sanofi Company (5) · University of Cincinnati (5) · Washington University School of Medicine (5) · Columbia University (4) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (4) · Stanford University (4) · The Korean Society of Pediatric Hematology Oncology (4) · University of Miami (4) · University of Nebraska (4)
United States (206) · Canada (15) · China (12) · France (11) · Italy (8) · Brazil (7) · Spain (7) · United Kingdom (7) · Germany (6) · South Korea (6) · Australia (5) · Austria (4) · Czechia (4) · Norway (4) · Sweden (4)
Richard Burt, MD (9) · Brandon Triplett, MD (4) · E. Steve Woodle, MD (4) · Richard E. Champlin, MD (4) · Damiano Rondelli, MD (3) · Michael Pulsipher, MD (3) · Robert Lowsky (3) · Sandeep Soni, MD (3) · Alexandra Gomez Arteaga, MD (2) · Arthur Matas, MD (2) · Chitra M. Hosing, MD (2) · Elizabeth Shpall, MD (2) · Issa Khouri (2)
PMID 17093248, PMID 20685256, PMID 24477186, PMID 26869630, PMID 30012675, PMID 32343796, PMID 36240296, PMID 39382091, PMID 1090310, PMID 12622583, PMID 16123718, PMID 16192477, PMID 16468960, PMID 16699456, PMID 18035553, PMID 18339140, PMID 18424759, PMID 18431244, PMID 18497677, PMID 18557726, PMID 19066739, PMID 19423725, PMID 19528536, PMID 19714613, PMID 20107229, PMID 20236866, PMID 20383216, PMID 20528878, PMID 20946966, PMID 21084848, PMID 21401720, PMID 21606164, PMID 21663651, PMID 21874061, PMID 21976674, PMID 21981661, PMID 22027927, PMID 22517900, PMID 22526363, PMID 22544699, PMID 22563089, PMID 22677206, PMID 22796534, PMID 22850297, PMID 23234514, PMID 23274902, PMID 23369458, PMID 23607606, PMID 24319166, PMID 24319167
P30CA016672 (4), P30CA015704 (3), U10HL069294 (3), 2009 (2), P01CA049605 (2), P01CA148600 (2), P01HL036444 (2), U24CA076518 (2), 1UG3HL157564-01A1 (1), 2008 (1), 2015 (1), 2017 (1), 2019 (1), K12HD043494 (1), P01CA015396 (1)